Revvity reported third‑quarter results with 2% overall revenue growth to $698.9 million and a 3% rise in diagnostics revenue driven by newborn screening and immunodiagnostics. The company cited mid‑single‑digit growth in Europe and software and reproductive health strength; China revenues declined in the low teens. Management raised adjusted EPS guidance and increased R&D and SG&A modestly while reaffirming 2025 revenue targets in a narrowed range. Diagnostics growth offset softness in life‑sciences solutions and academic/government demand, with software showing double‑digit gains. Revvity’s results signal steady demand from pharma and biotech customers for screening and immunodiagnostic services, while geographic headwinds in China remain a near‑term challenge.